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SUPPLEMENTARY NOTES
Original contains color plates.
All DTIC reproductions will be in black and white. DOD Award number DAMDI7-03-l-0484, "The Role of c-Src Activation in Prostate Tumor Progression", has as its goal an understanding of the mechanisms of how activation of the protein tyrosine kinase, Src, contributes to prostate tumor progression and how Src regulation in host osteoclasts regulates metastatic growth of prostate tumor cells in the bone.
In the first year of work, we have successfully developed cell lines from PC3 human prostate tumor cells that are constitutively increased in Src expression, or in which Src expression is induced by doxycyclin.
Using these cells, we have demonstrated that increased Src activity leads to increased expression of vascular endothelial growth factor (VEGF); a novel finding implicating Src in promotion of angiogenesis by prostate tumor cells.
We have further demonstrated that increased Src expression leads to increased tumorigenic growth in nude mice.
Thus, we have provided new evidence that Src activation is important to prostate tumor progression.
To examine the role of Src in growth of prostate tumor cells in the bone, we have begun to develop a Src-/-nu/nu strain of mice. Breeding of these mice is underway and two generations of mice have been obtained. Continued studies should provide new insights into role of Src in both the tumor and host environment in promoting prostate tumor cell metastasis. INTRODUCTION DOD Award number DAMD17-03-1-0484, "The Role of c-Src Activation in Prostate Tumor Progression", has as its goal an understanding of the mechanisms of how activation of the protein tyrosine kinase, Src, contributes to prostate tumor progression and how Src regulation in host osteoclasts regulates metastatic growth of prostate tumor cells in the bone. Many epigenetic events contribute to prostate tumor progression, including increased expression of growth factor receptors. When overexpressed, growth factor receptors often constitutively associate with cSrc, resulting in Src activation. Activated Src then contributes to many tumor functions, including resistance to apoptosis and increased expression of angiogenic factors (reviewed by Summy and Gallick, 2003) . In prostate cancer cells, we have demonstrated that this activation correlates with increased Vascular Endothelial Growth Factor (VEGF) expression (Kim et al., 2003) . However, understanding which functions in tumor progression require Src activation, and the mechanism(s) by which Src contributes to these processes remains unknown, and is a focus of the studies for which this grant was awarded. To complete the tasks we originally proposed, development of prostate tumor cell lines with increased and/or decreased Src expression was required. As discussed below, we have been successful in this endeavor, and have proceeded to finish most of Task 1 (analysis of VEGF expression). Task 2 (resistance to apoptosis) will proceed now that the required cell lines have been generated. Task 3 was to examine tumorigenicity in a Src +/+ and Src-/-background. We have begun analysis in the Src +/+ background, as described below. The rationale for use of the Src-/-background is that, in addition to its role in tumor cells, Src plays a pivotal role in osteoclast function, with Src-/-mice suffering from osteopetrosis, due to defective osteoclasts failing to properly mediate bone remodeling (Soriano et al., 1991) . Thus, the other goal of studies in this grant is to determine tumorigenicity in this background. To complete Task 3, we will be required to breed the Src-/-mice into an nu/nu background, exactly as originally proposed. This is necessary because immunocompetent mice will reject human tumor cells. As described below, our breeding program is well under way. Thus, we have made substantial progress in the first year of funding for this grant.
SUBJECT
BODY Task 1
The initial part of Task 1 was to determine the effects of c-Mt and PTEN/MMAC on Src activity and VEGF expression. These studies have been completed, some of them prior to the grant funding beginning. We determined that decreased c-Met expression resulted in decreased Src activation and decreased VEGF expression (Kim et al., 2003) ; whereas ectopic expression of PTEN/MMAC had no effect on Src activity and no effect on VEGF expression.
Next, we used pharmacologic inhibitors of Src to determine their effect on VEGF expression. Using the Src inhibitor PP2, we demonstrated a decrease in VEGF expression correlating with decreased Src activity. While suggestive of Src regulating VEGF expression, the lack of selectivity of this inhibitor does not allow definitive conclusions with respect to Src regulation of VEGF expression. Therefore, as originally proposed, we have generated clones of
the low-metastatic PC3 cells that ectopically express Src. These clones are required for the completion of all the proposed tasks, and have been a focus of the studies of year 1. Two strategies were used to generate these clones. First, we transfected PC3 cells with a Src expression vector (Src "driven" from a CMV promoter in PCDNAIII, expressing a neomycinresistance gene) that we have used in the past in other cell types (Windharn et al., 2002) . G418-resistant colonies were isolated and expanded. Several colonies were obtained with increased Src expression. Some of the PC3-transfectants ectopically expressing Src are shown in Figure 1 clones are shown in Figure 2 . As a second approach to increasing Src expression in PC3 cells, we used a tetracyclineinducible vector system. This system has the advantage of direct comparison of Src induced in the same cells, thus avoiding concerns due to clonal variation.
PC-3 cells were transfected with a plasmid that expressed the TET-on protein (Clonetech) and stable clones were selected with G418. PC-3 resistant G418 clones were screened for expression of the tet-protein by transiently transfecting with luciferase plasmid that was induced by the tetprotein in the presence of doxycyclin. Positive clones were then transfected with the secondary plasmid with the Src gene downstream of the tet-binding protein promoter and selected by hygromycin. Resistant clones were checked for Src-expression by treating clones for 48 h in presence of 1.5 Rg/ml doxycylin and running western analysis with the EC 10 antibody, specific for chicken c-Src. We first designed and selected clones with the activating Y527F mutation, as they would be expected to be more tumorigenic. Several inducible clones were obtained, two of which are shown in Figure 3 . As shown in Figure 3 , Src is induced to high levels in these clones, 
Clones and times after Src Induction
Upon addition of 1.5 [tg/ml doxycylin, VEGF is induced to levels approaching four fold that observed in uninduced and control cells. We have begun tumorigenicity studies on these clones as part of Task 3. The results are described under progress for this task, below. Thus, by multiple approaches we have demonstrated that Src regulates VEGF expression in prostate tumor cells, essentially completing Task 1. DAMD17-03-1-0484 2004 Annual Report Gary E. Gallick, Ph.D. Task 2 Task 2 is to determine the role of c-Src expression in inhibition of apoptosis. This task has commenced as yet, although completion of the task required the generation of the cell lines described above. We anticipate work on this task will commence in year 2.
Task 3
Task 3 is to determine the effect of Src expression on growth and metastasis of human prostate tumor cells in orthotopic mouse models. As indicated in the introduction, there are two mouse models to be employed in these studies: "standard" nude mice and Src-/-nude mice, the latter of which need to be developed as described in the initial proposal. We have begun both components of this task. First, we determined the ability of the tet-inducible PC3/Src clones to grow subcutaneously in nude mice. For these studies, 5 x 105 cells were injected subcutaneously into nude mice. Five mice were given standard water; to an identical group of 5 mice, 1Omg/ml doxycyclin was added to the drinking water. Each of the mice developed tumors. However, as shown in Figure 5 , tumor growth was considerably more rapid in animals receiving use of the inducible system will become the primary strategy for regulating Src expression for in vivo studies. Thus, we will begin orthotopic injections and metastasis studies in the coming year.
Generation of Src-/-nu/nu mice This task has commenced. As described in the proposal, 8 generations of back breeding will be required to obtain Src-/-mice in the desired background. We are currently on our second back breeding. To determine that we can correctly identify the Src-/-phenotype, DNA from tail snips is purified, and Polymerase Chain Reaction (PCR) performed to identify the wild type and mutant allele. An example of the PCR results is shown in Figure 6 . As can be seen, both wild type (200bp product) and mutant (450bp product) can be identified in the heterozygous mice; whereas only the wild type allele is identified in homozygous (wt) mice. Thus, we are successfully able to screen for progeny with the correct phenotype. We will continue the breeding in year 2, and expect to be able to perform tumorigenicity studies in the Src-/-nu/nu mice in year 3.
